Dumont & Blake Investment Advisors LLC lowered its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,451 shares of the medical research company’s stock after selling 75 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $951,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of TMO. Vanguard Group Inc. boosted its stake in Thermo Fisher Scientific by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after buying an additional 695,079 shares during the last quarter. BlackRock Inc. boosted its stake in Thermo Fisher Scientific by 2,692.1% in the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after buying an additional 22,165,530 shares during the last quarter. State Street Corp boosted its stake in Thermo Fisher Scientific by 1.0% in the 1st quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock worth $2,470,802,000 after buying an additional 164,367 shares during the last quarter. Wellington Management Group LLP boosted its stake in Thermo Fisher Scientific by 5.6% in the 1st quarter. Wellington Management Group LLP now owns 7,512,152 shares of the medical research company’s stock worth $1,153,867,000 after buying an additional 398,622 shares during the last quarter. Finally, Morgan Stanley boosted its stake in Thermo Fisher Scientific by 7.6% in the 1st quarter. Morgan Stanley now owns 4,664,882 shares of the medical research company’s stock worth $716,526,000 after buying an additional 327,826 shares during the last quarter. 83.52% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.themarketsdaily.com/2017/09/13/dumont-blake-investment-advisors-llc-has-951000-position-in-thermo-fisher-scientific-inc-tmo.html.
Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at 194.04 on Wednesday. The stock has a market capitalization of $75.70 billion, a P/E ratio of 33.80 and a beta of 1.05. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $194.30. The company’s 50 day moving average price is $178.63 and its 200 day moving average price is $169.74.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. During the same quarter in the previous year, the company posted $2.03 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, equities analysts expect that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.45%.
A number of analysts have issued reports on the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price target on the stock in a research note on Thursday, September 7th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Morgan Stanley reissued an “overweight” rating and issued a $220.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. Finally, BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Two analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $193.19.
In other news, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the sale, the vice president now owns 19,751 shares in the company, valued at approximately $3,657,490.18. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jim P. Manzi sold 11,318 shares of the company’s stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $172.94, for a total value of $1,957,334.92. Following the sale, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The disclosure for this sale can be found here. Insiders sold 22,738 shares of company stock worth $4,021,512 in the last 90 days. Corporate insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.